CDDO-Me alleviates doxorubicin/lapatinib-induced cardiotoxicity by activating the NRF2/GPX4 axis to inhibit oxidative stress and ferroptosis - PubMed
5 hours ago
- #Cardiotoxicity
- #Ferroptosis
- #CDDO-Me
- CDDO-Me reduces cardiotoxicity from doxorubicin and lapatinib combination in mice, improving cardiac function and reducing fibrosis.
- CDDO-Me activates the NRF2/GPX4 axis, stabilizing GPX4 to inhibit ubiquitin-proteasome degradation and ferroptosis.
- The compound restores glutathione levels, suppresses lipid peroxidation, and mitigates mitochondrial dysfunction and iron overload.
- CDDO-Me does not interfere with the antitumor efficacy of doxorubicin and lapatinib in breast cancer cells.
- The study suggests CDDO-Me as a therapeutic strategy to protect heart function during chemotherapy without compromising cancer treatment.